Health News (Reuters)

FDA approves Gilead's Yescarta cancer immunotherapy

(Reuters) - A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of schedule.

U.S. FDA panel backs approval of Novo Nordisk diabetes drug

WASHINGTON (Reuters) - Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

U.S. judge says he may reject plea deal with Novelion's Aegerion

BOSTON (Reuters) - A U.S. judge on Wednesday said he may reject a plea agreement that was part of Aegerion Pharmaceuticals Inc's recent $36 million settlement with the U.S. Justice Department, saying he was not happy with its sentencing terms.

White House says Trump opposes Senate's bipartisan Obamacare deal

WASHINGTON (Reuters) - A bipartisan deal from two senators to stabilize Obamacare by restoring subsidies to health insurers suffered major setbacks on Wednesday with the White House saying President Donald Trump now opposes it and senior Republicans speaking out against it.

Epidurals may not make labor last longer

(Reuters Health) - Giving pregnant women spinal anesthesia known as an epidural to ease their pain during the late stages of labor and delivery may not prolong the process, a new experiment suggests.

Trump backs away from Senate deal on stabilizing Obamacare

WASHINGTON (Reuters) - President Donald Trump on Wednesday backed away from a bipartisan deal from two U.S. senators to stabilize Obamacare by restoring subsidies to health insurers, one day after signaling his support for the plan.

Cancer drug prices rising far faster than inflation

(Reuters Health) - The prices of injectable cancer drugs - even older medicines around since the 1990s - are increasing at a rate far higher than inflation, researchers report in the Journal of Clinical Oncology.

Allergan ruling casts doubt on tribal patent strategy

(Reuters) - A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Plague ruled out in Seychelles but islands on guard: WHO

GENEVA (Reuters) - Plague has been ruled out in the Seychelles following lab results from 10 patients, including one earlier deemed a "probable" case, the World Health Organization (WHO) said on Wednesday as the disease continued to spread in Madagascar.

Alnyalm, Vir partner on RNAi-based hep B treatment

(Reuters) - Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.

Senate backers of deal to stabilize Obamacare seek to build support

WASHINGTON (Reuters) - Proponents of a bipartisan deal struck by two U.S. senators to stabilize Obamacare were seeking on Wednesday to win Republican support for the measure, which would restore subsidies to health insurers that President Donald Trump has scrapped.

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON (Reuters) - U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

McDonald's South Korea office raided in burger probe: reports

SEOUL (Reuters) - South Korean investigators raided the Seoul office of McDonald's Corp on Wednesday, following a series of complaints that children fell ill after eating hamburger patties alleged to have been undercooked, Yonhap News Agency and other media said.

Allergan ruling casts doubt on tribal patent strategy

(Reuters) - A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Pages